A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2

(1) Background: We previously reported the development of a recombinant protein SARS-CoV-2 vaccine, consisting of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, adjuvanted with aluminum hydroxide (alum) and CpG oligonucleotides. In mice and non-human primates, our wild-type (WT)...

Descripción completa

Detalles Bibliográficos
Autores principales: Thimmiraju, Syamala Rani, Adhikari, Rakesh, Villar, Maria Jose, Lee, Jungsoon, Liu, Zhuyun, Kundu, Rakhi, Chen, Yi-Lin, Sharma, Suman, Ghei, Karm, Keegan, Brian, Versteeg, Leroy, Gillespie, Portia M., Ciciriello, Allan, Islam, Nelufa Y., Poveda, Cristina, Uzcategui, Nestor, Chen, Wen-Hsiang, Kimata, Jason T., Zhan, Bin, Strych, Ulrich, Bottazzi, Maria Elena, Hotez, Peter J., Pollet, Jeroen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610638/
https://www.ncbi.nlm.nih.gov/pubmed/37896960
http://dx.doi.org/10.3390/vaccines11101557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610638/
https://www.ncbi.nlm.nih.gov/pubmed/37896960
http://dx.doi.org/10.3390/vaccines11101557

Ejemplares similares